Bleeding Tolerance Among Patients With Atrial Fibrillation on Oral Anticoagulation

Gabriela Rusin1, Małgorzata Konieczyńska2, Piotr Bijak2

  • 1Department of Neurology, Jagiellonian University Medical College, Kraków, Poland.

Insights

Older age and previous bleeding or stroke events significantly influence how many bleeds patients with atrial fibrillation (AF) will accept while on oral anticoagulation therapy. AF knowledge level did not impact this acceptance.

Area of Science:

  • Cardiology
  • Internal Medicine
  • Thrombosis Management

Background:

  • Oral anticoagulation is crucial for preventing stroke in atrial fibrillation (AF) but increases bleeding risk.
  • Patient acceptance of this therapy is influenced by their perception of bleeding risk versus stroke prevention.
  • Understanding factors affecting bleeding acceptance is vital for long-term treatment adherence.

Purpose of the Study:

  • To investigate the impact of clinical factors and atrial fibrillation (AF) knowledge on bleeding acceptance in anticoagulated AF patients.
  • To identify patient characteristics associated with a lower tolerance for bleeding events during anticoagulation.

Main Methods:

  • 173 consecutive anticoagulated AF outpatients were assessed for their 'bleeding ratio' – the number of major bleeds they would tolerate to prevent one stroke.
  • The Jessa AF Knowledge Questionnaire was used to evaluate patients' understanding of AF.
  • Statistical analysis identified independent predictors of a low bleeding ratio.

Main Results:

  • Older age, longer AF duration, heart failure, and prior cerebrovascular events were associated with a lower bleeding ratio.
  • Patients with a history of major or minor bleeds on anticoagulation had a significantly lower bleeding ratio.
  • The level of AF knowledge did not significantly affect the bleeding ratio.

Conclusions:

  • Age and a history of thromboembolic or bleeding events are key determinants of bleeding acceptance in anticoagulated AF patients.
  • These findings can help identify AF patients who may require additional support to improve acceptance of long-term oral anticoagulation therapy.
Abstract

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.9K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.5K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
231
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.9K
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
157
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
984